Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 2, 2010, Pages 106-115

  Kane, John M ^a   Cohen, Michael ^b   Zhao, Jun ^b   Alphs, Larry ^c   Panagides, John ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; HALOPERIDOL; PLACEBO;

AGITATION; AKATHISIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPESTHESIA; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; VOMITING; WEIGHT GAIN;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; PARKINSONIAN DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77952154800     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181d35d6b     Document Type: Article

References (51)

1. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68(2):e04.
2. Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006;88(1-3):5-25. (Pubitemid 44693240)
3. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13-24. (Pubitemid 46148428)
4. Mcintosh AM, Cordon L, Lawrie SM, et al. Compliance therapy for schizophrenia. Cochrane Database Syst Rev. 2006;3:CD003442.
5. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21. (Pubitemid 43046108)
6. Droulout T, Liraud F, Verdoux H. Relationships between insight and medication adherence in subjects with psychosis. Encephale. 2003;29(5):430-437. (Pubitemid 37356174)
7. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235-244. (Pubitemid 46164772)
8. Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106-113. (Pubitemid 351282003)
9. Shahid M, Walker G, Zom S, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
10. Saphris®Schering-Plough, Kenilworth, NJ. 2009.
11. Peeters PAM, Bockbrader H, Spaans E, et al. Asenapine Pharmacokinetics: Influence of Hepatic and Renal Impairment. Presented at: American. Psychiatric Association; May 3-8, 2008; Washington, DC.
12. Dogterom P, Hulskotte EGJ, Gerrits MGF, et al. Asenapine Pharmacokinetics: Influence of Cytochrome P450 Modulators and UDP-Glucuronyltransferase Inhibition. Presented at: 21st Congress European College of Neuropsychopharmacology; February 3-7, 2008; Barcelona, Spain.
13. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492-1500. (Pubitemid 350073395)
14. Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother. 2006;7(13):1739-1748.
15. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10): 1079-1087. (Pubitemid 44498387)
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. (Pubitemid 18039085)
17. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546. (Pubitemid 28100274)
18. Guy W Clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976:217-222.
19. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247-251.
20. Lindenmayer JP, Czobor P, Alphs L, et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res. 2003;63(1-2):161-170. (Pubitemid 36934486)
21. Potkin SG, Gharabawi GM, Greenspan AJ, et al. Psychometric evaluation of the Readiness for Discharge Questionnaire. Schizophr Res. 2005; 80(2-3 ): 203-212. (Pubitemid 41713646)
22. Simpson GM, Angus JW A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
24. Guy W. Abnormal involuntary movement scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976: 534-537.
25. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel. Trial 13 Study Group. Biol Psychiatry. 1997;42(4):233-246.
26. Beasley CM Jr, Hamilton. SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7(2):125-137.
27. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996; 124(1-2): 159-167. (Pubitemid 126424654)
28. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996; 14(2): 111-123. (Pubitemid 26050500)
29. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 suppl 1):S20-S28.
30. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5): 491-505.
31. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1-3):117-130. (Pubitemid 46817944)
32. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial, Schizophr Res. 2007;90( 1 -3): 147-161. (Pubitemid 46178537)
33. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. AmJ Psychiatry. 1994; 151 (6): 825-835.
34. Bames SA, Mallinckrodt CH, Lindborg SR, et al. The impact of missing data and how it is handled on the rate of false-positive results in drug development. Pharm Stat. 2008;7(3):215-225.
35. Whitehead C, Moss S, Cardno A, et al. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2002;(2):CD002305.
36. Perenyi A, Forlano R. Suicide in schizophrenia. Neuropsychopharmacol Hung. 2005;7(3): 107-117.
37. Moller HJ. Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):83-93.
38. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12): 1917-1928.
39. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
40. Waraich PS, Adams CE, Roque M, et al. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst Rev. 2002;(3):CD001951.
41. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14(3): 163-173. (Pubitemid 36172565)
42. Laporte JR, Figueras A, Placebo effects in psychiatry. Lancet. 1994;344(8931): 1206-1209.
43. Stein DJ, Baldwin DS, Dolberg OT, et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67(11):1741-1746.
44. Stolk P, Ten Berg MJ, Hemels ME, et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother. 2003;37(12):1891-1899. (Pubitemid 37466590)
45. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840- 1847. (Pubitemid 34303629)
46. Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry. 1997;58(suppl 12): 18-22. (Pubitemid 27516506)
47. Sysko R, Walsh BT. A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry. 2007;68(8): 1213-1217. (Pubitemid 47395623)
48. Keck PE Jr, Welge JA, Strakowski SM, et al. Placebo effect in randomized, controlled maintenance studies of patients with bipolar disorder. Biol Psychiatry. 2000;47(8):756-761. (Pubitemid 30201673)
49. Keck PE Jr, Welge JA, McElroy SL, et al. Placebo effect in randomized, controlled studies of acute bipolar mania and depression, Biol Psychiatry. 2000;47(8):748-755. (Pubitemid 30201672)
50. Welge JA, Keck PE Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl). 2003;166(1):1-10. (Pubitemid 36286715)
51. Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord. 2003:73(1-2): 155-161. (Pubitemid 36044643)